Dr. Liping Liu
Founder and CEO, HighTide Therapeutics, Inc., Greater China
Liping Liu is the Founder and CEO of HighTide Therapeutics, a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases. HigTide Therapeutics, headquartered in China, was established in 2011.
In 2010, the Chinese government announced the "Twelfth Five-Year Plan," with the aim to support biotechnology to become one of the leading emerging industries. Liping worked for several biotech companies engaged in innovative drug research and development for over a decade. She decided to return to China to apply her drug discovery and development experience and establish a company focusing on major unmet medical needs in the fields of metabolic diseases and digestive diseases.
The strategic vision of HighTide is to become a global leader in innovative biotechnology and develop new drugs that will help patients around the world, and to realize the clinical and commercial value of the company. Today, HighTide has developed more than 10 assets with large market potential and has more than 50 patents granted.
Liping earned a PhD in Chemistry in 1994 from Nankai University and completed her postdoctoral research at the University of Toronto, Canada. She also holds an MBA from Johns Hopkins University Carey Business School.
Our vision is to become a leading and respected globally integrated biotech company. We focus on patient-centric drug development and are devoted to managing the health of patients with sincerity and kindness to improve the comprehensive clinical benefits and overall health of patients.
